VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update

Core Viewpoint - VolitionRx Limited reported significant progress in commercializing its Nu.Q® platform for human diagnostics, with new agreements and positive financial results for Q3 2025 [2][4][8]. Financial Highlights - Revenue for Q3 2025 was $0.6 million, reflecting a 32% increase compared to the same quarter last year [8]. - Operating expenses decreased by 10% year-on-year, and by 18% for the first three quarters of 2025 [8]. - Net loss reduced by 8% for the quarter and by 20% for the first three quarters compared to the previous year [8]. - Net cash used in operating activities was $3.6 million for the quarter, down 33% from the same period last year [8]. - The company received approximately $6.1 million in net proceeds from a public offering after the quarter ended [8]. Business Developments - Volition signed two significant agreements: a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome with Werfen, and a Co-Marketing and Services Agreement with Hologic [2][3]. - The company is in discussions with around 10 leading diagnostic and liquid biopsy companies, indicating potential for further licensing deals [4]. - Volition aims to replicate its successful licensing strategy in the veterinary market within the human diagnostics space, anticipating diverse deal structures [6]. Technology and Research - The Nu.Q® technology shows promise in critical areas such as cancer and sepsis, with ongoing publications expected in the coming quarters [5]. - The company is focused on developing blood tests for early detection and monitoring of diseases, which could significantly improve patient outcomes [12].